Difficulty: Medium
Average Score: 66%
Practice
The antimuscarinic agent preferred in the management of motion sickness is
Correct answer
B
Rationale
The correct answer is B) Scopolamine. Scopolamine is the preferred antimuscarinic agent in the management of motion sickness due to its ability to effectively block the action of acetylcholine at muscarinic receptors in the vestibular system. This helps alleviate symptoms like nausea and dizziness associated with motion sickness.
Atropine methonitrate (Option A) is not preferred for motion sickness as it is more commonly used for other indications like bradycardia or organophosphate poisoning. Homatropine methyl bromide (Option C) is mainly used as a mydriatic agent in ophthalmology and not for motion sickness. Ipratropium bromide (Option D) is primarily used as a bronchodilator in conditions like COPD and asthma, not for motion sickness.
Educationally, understanding the mechanism of action of different antimuscarinic agents is crucial for healthcare professionals to make informed decisions in prescribing the appropriate medication for specific conditions. In the context of motion sickness, selecting the right antimuscarinic agent like scopolamine can significantly improve patient outcomes and quality of life during travel or other motion-related activities.
Atropine methonitrate (Option A) is not preferred for motion sickness as it is more commonly used for other indications like bradycardia or organophosphate poisoning. Homatropine methyl bromide (Option C) is mainly used as a mydriatic agent in ophthalmology and not for motion sickness. Ipratropium bromide (Option D) is primarily used as a bronchodilator in conditions like COPD and asthma, not for motion sickness.
Educationally, understanding the mechanism of action of different antimuscarinic agents is crucial for healthcare professionals to make informed decisions in prescribing the appropriate medication for specific conditions. In the context of motion sickness, selecting the right antimuscarinic agent like scopolamine can significantly improve patient outcomes and quality of life during travel or other motion-related activities.